


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (Currently Amended) A compound of formula (I)



including enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts, thereof wherein:

A, B, D, and E, are selected from N or C, X and Y are both N, and exactly one of A, B, D, and E is N;

M is CH or N;

Z is C(=O)GR<sup>2</sup> or C(H)<sub>2</sub>GR<sup>2</sup>;

G is O or NH or none, or when Z is C(=O)GR<sup>2</sup>, G can also be alkylene ~~includes 1, 2 propylene;~~

n is 0-4;

R<sup>1</sup> is selected from halogen, -CN, -CF<sub>3</sub>, substituted alkyl, aryl, and heteroaryl;

R<sup>2</sup> is a 5- to 6-membered heterocycloalkyl containing one N; and

R<sup>4</sup> and R<sup>5</sup> are H;

or R<sup>4</sup> and R<sup>5</sup> may be taken together with the atoms to which they are attached to form a ring wherein the ring is selected from piperidine and piperazine; and

R<sup>10</sup> is selected from H, alkyl, substituted alkyl, alkenyl, and substituted alkenyl.

2. (Previously Presented) A compound of claim 1 including enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts, thereof wherein:

A is N;

B, D<sub>1</sub> and E are CH;

n is 2;



R<sup>1</sup> is selected from halogen, -CN, -CF<sub>3</sub>, substituted alkyl, aryl, and heteroaryl; and


R<sup>2</sup> is a piperidine or pyrrolidine ring.

3. (Canceled)


4. (Canceled)

5. (Previously Presented) A compound of claim 2 including enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts, thereof selected from:





and



6. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

7. – 12. (Canceled)